Uneek Mehra joined BBOT in July 2025. Most recently, Uneek served as Chief Financial & Business Officer at 4D Molecular Therapeutics (4DMT) where he led a successful $325M financing as well as capital allocation efforts to ensure funding for two large Phase 3 programs. Prior to that, he was the Chief Financial and Business Officer at Myovant Sciences Ltd., a public biopharma company, where he successfully built partnerships, and enabled significant commercial growth for its Oncology and Women’s Health products. He also led Myovant Sciences’ acquisition by Sumitomo Pharma. His earlier leadership roles include Chief Financial Officer at PACT Pharma and Proteus Digital Health as well as 13 years at Novartis, where he led strategic capital allocation and drove commercial financial performance for multi-billion-dollar businesses. He began his career in senior finance roles at IBM and Citibank before moving into healthcare.

Uneek holds an MBA in Strategy and Leadership from the International Institute for Management Development (IMD) in Lausanne, Switzerland, a Master of Management Studies (MMS) in Finance from the University of Mumbai, and a Bachelor of Engineering in Electronics from the Birla Institute of Technology and Science (BITS), Pilani, India.